guanfacine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, guanidine derivatives 1343 29110-47-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • guanfacine
  • guanfacine hydrochloride
  • guanfacine HCl
  • guanfacine monohydrochloride
A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
  • Molecular weight: 246.09
  • Formula: C9H9Cl2N3O
  • CLOGP: 1.37
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 78.97
  • ALOGS: -3.25
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 81 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 5.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.28 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.367 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.021 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 21.827 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.051 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 25.350 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 47.930 % High 1
herg hERG pIC50 4.941 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.542 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 5.176 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 24.790 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 70
kinase-selectivity-class AXL,BRAF,CSF1R,DDR1,EIF2AK3,EPHB4,GRK2,LYN,MAPK7,PDK4,SIK2 11
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.333 High 1
mh-clint Mouse hepatocyte intrinsic clearance 16.904 High 1
mppb Mouse plasma protein binding (% unbound) 26.140 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.166 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 29.090 % High 1
rh-clint Rat hepatocyte intrinsic clearance 18.535 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.020 % High 1
rppb Rat plasma protein binding (% unbound) 27.920 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 659.174 uM High 1

Approvals:

DateAgencyCompanyOrphan
March 30, 2017 PMDA Shionogi & Co., Ltd.
Oct. 27, 1986 FDA PROMIUS PHARMA
Sept. 17, 2015 EMA Takeda Pharmaceuticals International AG Ireland Branch

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 208.91 23.74 97 4132 93737 90530481
Bradycardia 145.10 23.74 73 4156 83774 90540444
Electrocardiogram QT prolonged 116.33 23.74 60 4169 72396 90551822
Product substitution issue 111.68 23.74 39 4190 17969 90606249
Somnolence 107.26 23.74 84 4145 209000 90415218
Aggression 100.23 23.74 40 4189 26628 90597590
Suicidal ideation 74.27 23.74 45 4184 73810 90550408
Overdose 73.59 23.74 60 4169 157649 90466569
Toxicity to various agents 67.87 23.74 75 4154 287771 90336447
Intentional self-injury 67.19 23.74 31 4198 29303 90594915
Hypotension 65.30 23.74 78 4151 325319 90298899
Impulsive behaviour 63.48 23.74 15 4214 1715 90622503
Distributive shock 62.54 23.74 17 4212 3407 90620811
Abnormal behaviour 61.66 23.74 27 4202 22601 90601617
Sinus bradycardia 55.36 23.74 23 4206 16929 90607289
Product administered to patient of inappropriate age 53.05 23.74 16 4213 4637 90619581
Bradypnoea 53.03 23.74 16 4213 4642 90619576
Psychomotor hyperactivity 47.36 23.74 19 4210 12794 90611424
Blood pressure decreased 44.69 23.74 33 4196 74862 90549356
Suicide attempt 42.26 23.74 32 4197 75367 90548851
Self-destructive behaviour 38.88 23.74 8 4221 483 90623735
Cerebral disorder 37.86 23.74 13 4216 5681 90618537
Off label use 37.19 23.74 124 4105 1102128 89522090
Coma 34.59 23.74 28 4201 72604 90551614
Irritability 33.95 23.74 21 4208 35641 90588577
Atrioventricular dissociation 31.84 23.74 6 4223 229 90623989
Sinus arrhythmia 30.26 23.74 8 4221 1441 90622777
Syncope 30.20 23.74 34 4195 132629 90491589
Attention deficit hyperactivity disorder 29.57 23.74 10 4219 4174 90620044
Sedation 28.22 23.74 21 4208 48150 90576068
Upper airway obstruction 27.91 23.74 7 4222 1025 90623193
Educational problem 26.51 23.74 6 4223 567 90623651
Orthostatic hypotension 23.97 23.74 18 4211 41809 90582409
Anger 23.83 23.74 12 4217 13708 90610510

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 335.69 29.14 159 7079 44004 42570093
Product substitution issue 326.03 29.14 107 7131 11183 42602914
Agitation 151.04 29.14 108 7130 64206 42549891
Psychomotor hyperactivity 140.13 29.14 57 7181 10901 42603196
Abnormal behaviour 129.79 29.14 71 7167 26380 42587717
Bradycardia 119.84 29.14 106 7132 85378 42528719
Tic 117.14 29.14 34 7204 2349 42611748
Irritability 112.35 29.14 66 7172 28062 42586035
Somnolence 104.49 29.14 124 7114 140981 42473116
Impulsive behaviour 103.43 29.14 31 7207 2394 42611703
Electrocardiogram QT prolonged 102.22 29.14 76 7162 47869 42566228
Autism spectrum disorder 88.89 29.14 29 7209 2959 42611138
Dystonia 78.80 29.14 40 7198 12750 42601347
Intentional overdose 72.39 29.14 64 7174 51392 42562705
Drug ineffective 72.32 29.14 252 6986 629945 41984152
Anger 66.74 29.14 36 7202 12982 42601115
Sinus bradycardia 59.65 29.14 35 7203 14818 42599279
Insomnia 59.47 29.14 86 7152 118167 42495930
Suicidal ideation 56.25 29.14 54 7184 48107 42565990
Educational problem 55.56 29.14 14 7224 564 42613533
Attention deficit hyperactivity disorder 49.64 29.14 19 7219 3089 42611008
Product use issue 49.47 29.14 63 7175 76688 42537409
Disturbance in attention 45.71 29.14 39 7199 29827 42584270
Emotional disorder 45.57 29.14 22 7216 6292 42607805
Product administered to patient of inappropriate age 45 29.14 20 7218 4741 42609356
Brugada syndrome 42.91 29.14 13 7225 1040 42613057
Sedation 41.03 29.14 37 7201 30438 42583659
Oromandibular dystonia 40.32 29.14 11 7227 605 42613492
Product availability issue 40.31 29.14 17 7221 3550 42610547
Negativism 39.25 29.14 10 7228 421 42613676
Distractibility 38.56 29.14 10 7228 452 42613645
Hypertensive urgency 38.16 29.14 10 7228 471 42613626
Acute kidney injury 38.16 29.14 8 7230 367329 42246768
Accidental exposure to product by child 37.83 29.14 13 7225 1554 42612543
Nephrogenic diabetes insipidus 37.78 29.14 13 7225 1561 42612536
Behaviour disorder 37.53 29.14 20 7218 7034 42607063
Product quality issue 37.28 29.14 28 7210 17854 42596243
Intentional self-injury 36.67 29.14 26 7212 15176 42598921
Self-destructive behaviour 35.39 29.14 9 7229 376 42613721
Affect lability 35.08 29.14 16 7222 4028 42610069
Anxiety 35.06 29.14 68 7170 118492 42495605
Sinus arrest 33.78 29.14 13 7225 2143 42611954
Product dose omission issue 33.45 29.14 78 7160 154287 42459810
No adverse event 33.32 29.14 37 7201 38984 42575113
Withdrawal syndrome 32.74 29.14 24 7214 14751 42599346
Electrocardiogram QRS complex prolonged 32.36 29.14 17 7221 5806 42608291
Disturbance in social behaviour 32.34 29.14 12 7226 1791 42612306
Affective disorder 31.99 29.14 17 7221 5943 42608154
Death 31.17 29.14 21 7217 471164 42142933
Defiant behaviour 30.36 29.14 5 7233 20 42614077
Drug dose titration not performed 29.93 29.14 8 7230 407 42613690

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aggression 415.65 23.40 167 9743 59043 110520346
Product substitution issue 362.04 23.40 118 9792 22943 110556446
Bradycardia 265.38 23.40 168 9742 155349 110424040
Intentional overdose 261.31 23.40 157 9753 132344 110447045
Electrocardiogram QT prolonged 235.44 23.40 137 9773 108823 110470566
Psychomotor hyperactivity 165.96 23.40 64 9846 20213 110559176
Somnolence 163.42 23.40 165 9745 297284 110282105
Agitation 158.21 23.40 108 9802 112943 110466446
Impulsive behaviour 156.49 23.40 40 9870 3275 110576114
Abnormal behaviour 143.46 23.40 70 9840 38969 110540420
Irritability 141.37 23.40 74 9836 47735 110531654
Tic 125.76 23.40 34 9876 3459 110575930
Sinus bradycardia 111.72 23.40 54 9856 29429 110549960
Suicidal ideation 111.08 23.40 81 9829 93856 110485533
Autism spectrum disorder 99.31 23.40 25 9885 1923 110577466
Overdose 98.81 23.40 113 9797 233681 110345708
Intentional self-injury 85.86 23.40 49 9861 37380 110542009
Hypotension 85.03 23.40 161 9749 523688 110055701
Toxicity to various agents 84.65 23.40 153 9757 480402 110098987
Educational problem 76.64 23.40 16 9894 532 110578857
Anger 75.60 23.40 36 9874 18971 110560418
Product administered to patient of inappropriate age 71.61 23.40 27 9883 8009 110571380
Dystonia 65.20 23.40 36 9874 25769 110553620
Sedation 58.28 23.40 49 9861 69634 110509755
Attention deficit hyperactivity disorder 54.66 23.40 19 9891 4472 110574917
Blood pressure decreased 52.59 23.40 58 9852 115033 110464356
Bradypnoea 52.41 23.40 22 9888 8627 110570762
Drug ineffective 51.13 23.40 269 9641 1520271 109059118
Drug interaction 50.44 23.40 127 9783 500056 110079333
Lethargy 49.55 23.40 51 9859 93525 110485864
Self-destructive behaviour 48.73 23.40 12 9898 843 110578546
Accidental exposure to product by child 48.66 23.40 16 9894 3182 110576207
Brugada syndrome 45.84 23.40 13 9897 1575 110577814
Hyperammonaemia 45.60 23.40 23 9887 13709 110565680
Suicide attempt 45.34 23.40 51 9859 103343 110476046
Nephrogenic diabetes insipidus 44.43 23.40 14 9896 2431 110576958
Disturbance in attention 42.62 23.40 39 9871 61956 110517433
Product dose omission issue 42.61 23.40 91 9819 321691 110257698
Distributive shock 42.53 23.40 17 9893 5887 110573502
Syncope 41.43 23.40 69 9841 202467 110376922
Behaviour disorder 40.59 23.40 19 9891 9628 110569761
Oromandibular dystonia 39.85 23.40 11 9899 1208 110578181
Affective disorder 37.83 23.40 19 9891 11222 110568167
Off label use 37.72 23.40 246 9664 1499939 109079450
Mood swings 37.18 23.40 24 9886 22788 110556601
Withdrawal syndrome 36.91 23.40 27 9883 31353 110548036
Emotional disorder 36.63 23.40 21 9889 16139 110563250
Priapism 35.82 23.40 15 9895 5846 110573543
Hypertensive urgency 35.80 23.40 10 9900 1147 110578242
Device mechanical issue 34.34 23.40 11 9899 2013 110577376
Pain 33.90 23.40 22 9888 954933 109624456
Distractibility 33.51 23.40 9 9901 892 110578497
Sinus arrest 33.31 23.40 13 9897 4229 110575160
Insomnia 32.64 23.40 88 9822 360502 110218887
Seizure 32.12 23.40 65 9845 221120 110358269
Homicidal ideation 31.64 23.40 12 9898 3615 110575774
Disturbance in social behaviour 31.09 23.40 13 9897 5045 110574344
Anaemia 30.52 23.40 6 9904 547080 110032309
Completed suicide 30.30 23.40 67 9843 242314 110337075
Atrioventricular dissociation 30.07 23.40 7 9903 387 110579002
Tachycardia 29.86 23.40 64 9846 226581 110352808
Electrocardiogram QRS complex prolonged 29.72 23.40 17 9893 13004 110566385
Orthostatic hypotension 29.58 23.40 33 9877 66216 110513173
Joint swelling 29.01 23.40 3 9907 442842 110136547
Arrhythmia 28.26 23.40 33 9877 69542 110509847
Oppositional defiant disorder 28.16 23.40 7 9903 511 110578878
Respiratory depression 27.77 23.40 23 9887 31978 110547411
Defiant behaviour 27.62 23.40 5 9905 77 110579312
Drug dose titration not performed 27.53 23.40 8 9902 1057 110578332
Cerebral disorder 27.35 23.40 13 9897 6813 110572576
Gaming disorder 27.05 23.40 4 9906 15 110579374
Hallucination 26.94 23.40 39 9871 101393 110477996
Restlessness 26.81 23.40 29 9881 56230 110523159
Depressed level of consciousness 26.71 23.40 41 9869 112237 110467152
No adverse event 26.68 23.40 33 9877 73806 110505583
Presyncope 26.51 23.40 27 9883 48860 110530529
Arthralgia 26.26 23.40 19 9891 779613 109799776
Self-injurious ideation 26.15 23.40 11 9899 4335 110575054
Disruptive mood dysregulation disorder 25.80 23.40 4 9906 22 110579367
Sinus arrhythmia 25.71 23.40 9 9901 2161 110577228
Wrong technique in product usage process 25.29 23.40 35 9875 87313 110492076
Coma 25.22 23.40 41 9869 117828 110461561
Activation syndrome 25.07 23.40 6 9904 374 110579015
Mania 24.70 23.40 18 9892 20778 110558611
Anxiety 24.28 23.40 77 9833 345001 110234388
Diarrhoea 23.89 23.40 41 9869 1139464 109439925
Obsessive-compulsive disorder 23.66 23.40 12 9898 7229 110572160
Accidental overdose 23.45 23.40 26 9884 51808 110527581

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC02 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:176497 geroprotector
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists

Related Drugs by ATC class:

C02AC Imidazoline receptor agonists 4 drugs
clonidinemoxonidinerilmenidinetolonidine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Attention deficit hyperactivity disorder indication 406506008
Constipation contraindication 14760008 DOID:2089
Myocardial infarction contraindication 22298006 DOID:5844
Alcohol intoxication contraindication 25702006
Orthostatic hypotension contraindication 28651003
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007
Low blood pressure contraindication 45007003
End stage renal disease contraindication 46177005 DOID:784
Bradycardia contraindication 48867003
Cerebrovascular disease contraindication 62914000 DOID:6713
Heart block contraindication 233916004
Disease of liver contraindication 235856003 DOID:409
Syncope contraindication 271594007
Drowsy contraindication 271782001
Chronic myocardial ischemia contraindication 413844008 DOID:3393




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.71 acidic
pKa2 8.15 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR AGONIST EC50 7.16 WOMBAT-PK DRUG LABEL
5-hydroxytryptamine receptor 2B GPCR Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.12 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Ki 5.33 CHEMBL
Alpha-2B adrenergic receptor GPCR AGONIST EC50 5.93 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 6.07 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.26 DRUG MATRIX
Nischarin Membrane receptor Ki 7.72 CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 5.68 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR IC50 5.87 CHEMBL

External reference:

IDSource
4019771 VUID
N0000147862 NUI
D00606 KEGG_DRUG
29110-48-3 SECONDARY_CAS_RN
4019438 VANDF
4019771 VANDF
C0079466 UMLSCUI
CHEBI:5558 CHEBI
CHEMBL862 ChEMBL_ID
DB01018 DRUGBANK_ID
CHEMBL1200494 ChEMBL_ID
D016316 MESH_DESCRIPTOR_UI
3519 PUBCHEM_CID
522 IUPHAR_LIGAND_ID
3999 INN_ID
30OMY4G3MK UNII
203142 RXNORM
4809 MMSL
521 MMSL
6549 MMSL
d00717 MMSL
000650 NDDF
004497 NDDF
108553003 SNOMEDCT_US
108554009 SNOMEDCT_US
372507007 SNOMEDCT_US
30OMY4G3MK INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2850 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2851 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2853 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2855 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0444 TABLET 1 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0453 TABLET 2 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7140 TABLET 1 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-190 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-191 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-192 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 16714-193 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 28 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0711 TABLET 1 mg ORAL ANDA 13 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 24658-730 TABLET 1 mg ORAL ANDA 24 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 24658-731 TABLET 2 mg ORAL ANDA 24 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24979-198 TABLET 1 mg ORAL ANDA 13 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24979-199 TABLET 2 mg ORAL ANDA 13 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-533 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 28 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-534 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 28 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-536 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
Guanfacine Extended-Release HUMAN PRESCRIPTION DRUG LABEL 1 24979-538 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 28 sections
Guanfacine Human Prescription Drug Label 1 27241-242 TABLET 1 mg ORAL ANDA 10 sections
Guanfacine Human Prescription Drug Label 1 27241-243 TABLET 2 mg ORAL ANDA 10 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-458 TABLET 1 mg ORAL ANDA 21 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-459 TABLET 2 mg ORAL ANDA 21 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 29300-460 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 26 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 29300-461 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 29300-462 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 26 sections
Guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 29300-463 TABLET, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Guanfacine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-310 TABLET 1 mg ORAL ANDA 13 sections
guanfacine HUMAN PRESCRIPTION DRUG LABEL 1 42291-324 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 29 sections